Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Molecular Pharmacology
|
April 1, 1986
Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat
S A Wrighton, C Campanile, P E Thomas, et al.
The Journal of Clinical Investigation
|
May 15, 1997
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
K S Lown, D G Bailey, R J Fontana, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 10, 2014
Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI
J L Woodhead, K Yang, K L R Brouwer, et al.
Biochemistry
|
November 4, 1986
Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase
S A Wrighton, P E Thomas, D T Molowa, et al.
British Journal of Clinical Pharmacology
|
October 9, 1998
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease
R J Fontana, T M deVries, T F Woolf, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 1997
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test
C L Cheng, D E Smith, P L Carver, et al.
Clinical Pharmacology and Therapeutics
|
May 6, 2011
Case definition and phenotype standardization in drug-induced liver injury
G P Aithal, P B Watkins, R J Andrade, et al.
Clinical Pharmacology and Therapeutics
|
June 29, 2012
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers
A H Harrill, J Roach, I Fier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 14, 1997
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
P Schmiedlin-Ren, D J Edwards, M E Fitzsimmons, et al.
Clinical Pharmacology and Therapeutics
|
October 23, 1997
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
K S Lown, R R Mayo, A B Leichtman, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Molecular Pharmacology
|
April 1, 1986
Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat
S A Wrighton, C Campanile, P E Thomas, et al.
The Journal of Clinical Investigation
|
May 15, 1997
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
K S Lown, D G Bailey, R J Fontana, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 10, 2014
Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI
J L Woodhead, K Yang, K L R Brouwer, et al.
Biochemistry
|
November 4, 1986
Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase
S A Wrighton, P E Thomas, D T Molowa, et al.
British Journal of Clinical Pharmacology
|
October 9, 1998
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease
R J Fontana, T M deVries, T F Woolf, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 1997
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test
C L Cheng, D E Smith, P L Carver, et al.
Clinical Pharmacology and Therapeutics
|
May 6, 2011
Case definition and phenotype standardization in drug-induced liver injury
G P Aithal, P B Watkins, R J Andrade, et al.
Clinical Pharmacology and Therapeutics
|
June 29, 2012
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers
A H Harrill, J Roach, I Fier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 14, 1997
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
P Schmiedlin-Ren, D J Edwards, M E Fitzsimmons, et al.
Clinical Pharmacology and Therapeutics
|
October 23, 1997
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
K S Lown, R R Mayo, A B Leichtman, et al.
Page
of 10